21 CFR 314.170

§ 314.170 Adulteration and misbranding of an approved drug.

United States · 21 CFR — Food and Drugs · Status: effective

Cite this

Citation: 21 CFR 314.170, § 314.170 Adulteration and misbranding of an approved drug, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/86378
Permanent ID: ys:prov:86378@1
SHA-256: e21a702dba92ed7d1063b1271ddc2bdd411620bf2146d1a3577f9eaef4e443ec

The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.

Full text

All drugs, including those the Food and Drug Administration approves under section 505 of the act and this part, are subject to the adulteration and misbranding provisions in sections 501, 502, and 503 of the act. FDA is authorized to regulate approved new drugs by regulations issued through informal rulemaking under sections 501, 502, and 503 of the act.

Legislative history

This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.